{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:35:28Z","timestamp":1760524528622},"reference-count":19,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2023]]},"DOI":"10.3960\/jslrt.23023","type":"journal-article","created":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T22:39:54Z","timestamp":1693175994000},"page":"187-192","source":"Crossref","is-referenced-by-count":3,"title":["Acalabrutinib and steroid for autoimmune thrombocytopenia due to relapsed chronic lymphocytic leukemia with severe bone marrow infiltration"],"prefix":"10.3960","volume":"63","author":[{"given":"Takashi","family":"Oyama","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Yasunaga","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Jona","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, the University of Tokyo Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, the University of Tokyo Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Yatomi","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, the University of Tokyo Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Maki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Masamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mineo","family":"Kurokawa","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan,"},{"name":"Department of cell therapy and transplantation medicine, the University of Tokyo Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Hallek M, Cheson BD, Catovsky D <i>et al.<\/i> International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111: 5446-5456.","DOI":"10.1182\/blood-2007-06-093906"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Zent CS, Ding W, Schwager SM <i>et al.<\/i> The prognostic significance of cytopenia in chronic lymphocytic leukaemia\/small lymphocytic lymphoma. Br J Haematol. 2008; 141: 615-621.","DOI":"10.1111\/j.1365-2141.2008.07086.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Rogers KA, Woyach JA. Secondary autoimmune cytopenias in chronic lymphocytic leukemia. Semin Oncol. 2016; 43: 300-310.","DOI":"10.1053\/j.seminoncol.2016.02.011"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Hamblin TJ, Oscier DG, Young BJ. Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol. 1986; 39: 713-716.","DOI":"10.1136\/jcp.39.7.713"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Tsang M, Parikh SA. A concise review of autoimmune cytopenias in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2017; 12: 29-38.","DOI":"10.1007\/s11899-017-0366-1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Visco C, Barcellini W, Maura F <i>et al.<\/i> Autoimmune cytopenias in chronic lymphocytic leukemia. Am J Hematol. 2014; 89: 1055-1062.","DOI":"10.1002\/ajh.23785"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Visco C, Ruggeri M, Laura Evangelista M <i>et al.<\/i> Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood. 2008; 111: 1110-1116.","DOI":"10.1182\/blood-2007-09-111492"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Moreno C, Hodgson K, Ferrer G <i>et al.<\/i> Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood. 2010; 116: 4771-4776.","DOI":"10.1182\/blood-2010-05-286500"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Fattizzo B, Barcellini W. Autoimmune cytopenias in chronic lymphocytic leukemia: Focus on molecular aspects. Front Oncol. 2020; 9: 1435.","DOI":"10.3389\/fonc.2019.01435"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Lad DP, Varma S, Varma N <i>et al.<\/i> Regulatory T-cell and T-helper 17 balance in chronic lymphocytic leukemia progression and autoimmune cytopenias. Leuk Lymphoma. 2015; 56: 2424-2428.","DOI":"10.3109\/10428194.2014.986479"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Rogers KA, Ruppert AS, Bingman A <i>et al.<\/i> Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Leukemia. 2016; 30: 346-350.","DOI":"10.1038\/leu.2015.273"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Byrd JC, Brown JR, O\u2019Brien S <i>et al.<\/i> Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371: 213-223.","DOI":"10.1056\/NEJMoa1400376"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Rogers KA, Ruppert AS, Bingman A <i>et al.<\/i> Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Leukemia. 2016; 30: 346-350.","DOI":"10.1038\/leu.2015.273"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Jaglowski SM, Blazar BR. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD. Blood Adv. 2018; 2: 2012-2019.","DOI":"10.1182\/bloodadvances.2018013060"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Byrd JC, Hillmen P, Ghia P <i>et al.<\/i> Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial. J Clin Oncol. 2021; 39: 3441-3452.","DOI":"10.1200\/JCO.21.01210"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Arnold DM, Dentali F, Crowther MA <i>et al.<\/i> Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007; 146: 25-33.","DOI":"10.7326\/0003-4819-146-1-200701020-00006"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Visco C, Rodeghiero F, Romano A <i>et al.<\/i> Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study. Blood. 2019; 134: 1708-1711.","DOI":"10.1182\/blood.2019001617"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Seymour JF, Kipps TJ, Eichhorst B <i>et al.<\/i> Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018; 378: 1107-1120.","DOI":"10.1056\/NEJMoa1713976"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Byrd JC, Flynn JM, Kipps TJ <i>et al.<\/i> Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood. 2016; 127: 79-86.","DOI":"10.1182\/blood-2015-03-634394"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/3\/63_23023\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T05:17:51Z","timestamp":1715577471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/3\/63_23023\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.23023","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"23023"}}